Kisspeptin: What Lakeland Readers Should Know

Kisspeptin is a natural hormone that switches on the body’s reproductive system. Researchers have tested it in small studies for fertility treatment and low sexual desire, and some clinics and websites now promote it. This page explains what the research shows, how limited it is, and what FDA has said. It is general information, not advice for your situation.

What it is and how it works

Kisspeptin is made naturally in the body. It causes a part of the brain called the hypothalamus to release a hormone called GnRH. GnRH in turn leads to the release of LH and FSH, the hormones that control ovulation in women and sperm production in men.¹

Researchers mainly use two forms. Kisspeptin-54 is the longer one. Kisspeptin-10 is a shorter piece that is cleared from the blood much faster: in about 3 minutes, compared with about 28 minutes for kisspeptin-54.²

A key fact: the kisspeptin receptor can become less sensitive with repeated or continuous high doses. This is called tachyphylaxis, which means the body stops responding as strongly.²

What the research shows (and where evidence is weak)

Fertility (IVF). In IVF, a “trigger” shot is used to finish maturing the eggs before they are collected.

• In a first study of 53 women, a single injection of kisspeptin-54 triggered egg maturation. Embryos were transferred in 92%, and 23% had a clinical pregnancy. This study had no comparison group.³
• In a phase 2 trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS), a dangerous over-reaction to fertility drugs, eggs matured in 95% of women. Live birth rate per embryo transfer was 45%, and no woman developed moderate, severe or critical OHSS. The trial compared different doses of kisspeptin with each other, not with standard triggers.¹
• As of 2022, no forward-looking trial had compared kisspeptin head-to-head with standard IVF triggers.⁴

Hormone response over time. In women whose periods had stopped because of hypothalamic amenorrhea, kisspeptin-54 sharply raised LH and FSH at first. But after two weeks of repeated injections, the LH response fell from about 24 to about 2.5 units. This study had only 10 women. Its authors said this loss of response matters for any plan to use kisspeptin as an ongoing treatment.⁵

Low sexual desire in men. In a crossover trial, 32 men with hypoactive sexual desire disorder (HSDD) each received kisspeptin-54 and a placebo, on different days. It was given once, as a drip into a vein, in a lab. Kisspeptin changed activity in brain areas linked to sexual processing on brain scans. It also increased erection response to sexual videos, by up to 56% more than placebo.⁶ The study included only right-handed heterosexual men in a lab setting, and a single dose. A 2026 systematic review called kisspeptin “promising” for sexual desire but said the evidence base is limited.⁷

Where the evidence is weak:

• Small studies. Most have tens of people, are open-label (everyone knows what they got) or test a single dose in a lab.
• One research group. Nearly all human kisspeptin trials come from one research group in London. Its own reviews are not independent checks of its work.⁴²
• Lab measures are not real life. Brain scans and lab erection measures are not the same as better sexual function at home.⁶
• Different products. The studies used kisspeptin-54, injected or given by IV under research conditions. This research found no human trials of the kisspeptin-10 products sold online or by clinics, and no evidence for any home-use plan.

FDA and regulatory status

As of November 12, 2026, FDA’s drug database lists no kisspeptin product, and kisspeptin remains experimental.⁸

On September 29, 2023, FDA placed kisspeptin-10 on its “Category 2” list of compounding ingredients that may pose significant safety risks. As of April 22, 2026, it is still on that list. FDA cites possible immune reactions, impurities and trouble confirming what is in the ingredient. FDA also said it has little or no safety information for the proposed routes, so it cannot know whether the drug would cause harm in people.⁹ Unlike several other peptides, kisspeptin-10’s listing was not withdrawn.

For athletes, the 2026 WADA Prohibited List names “kisspeptin and its agonist analogues” as banned at all times.¹⁰

See our guides to compounded vs. FDA-approved peptides and research chemical peptide risks. If you are weighing kisspeptin against hormone therapy, see peptides vs. TRT and HRT.

Common side effects and safety

• FDA concerns. For compounded kisspeptin-10, FDA cites possible immune reactions, impurities and a lack of safety data.⁹
• In the IVF trial, no woman at high risk of OHSS developed moderate or severe OHSS.¹ Detailed side-effect tables from the trials were not reviewed for this page.
• Long-term safety is unknown. The studies were small and mostly short or single-dose, so they cannot show what happens with ongoing use.
• Loss of effect. Repeated dosing reduced the hormone response in the amenorrhea study.⁵

Products sold online as “research peptides” are not made to drug standards. Their purity and contents may not match the label.

Typical cost range

There is no approved product and no official price. We did not find reliable price data. Cost would depend on where a product comes from, visit and lab-test fees, and whether it is part of a research or fertility program. Ask any provider for a written price breakdown before you start.

See our cost guide for questions to ask about fees.

Questions to ask a provider

• What is causing my symptoms, and have my hormone levels been checked?
• Is there an FDA-approved treatment for my situation?
• Which form of kisspeptin are you offering, and has that form been tested in people?
• How do you account for the body becoming less responsive with repeated doses?
• Where does the product come from, given that FDA lists kisspeptin-10 as a safety risk for compounding?
• Am I a competitive athlete subject to drug testing?

For related topics, see the sexual health goal page.